Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects

Clinical Trial
Study Details
Enrollment
24
Interventions
Description

GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam

Name
GBT440
Type
Drug
Phase
Phase 1
Status
COMPLETED
Study ID #
NCT02567682
Study Type
Interventional
Summary

The purpose of this study to evaluate the effect of concomitant administration of GBT440 on caffeine (a CYP1A2 probe substrate), S warfarin (a CYP2C9 probe substrate), omeprazole (a CYP2C19 probe substrate), and midazolam (a CYP3A4 probe substrate) plasma concentrations.

Study Overview
Conditions
Sickle Cell Disease
Contacts and Locations
Locations
Facility

ICON Early Phase Services, LLC Clinical Research Unit
San Antonio, Texas 78209
United States

GeoPoint
29.42412, -98.49363